Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03042702 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer
A Phase 2 study of Ovarian Cancer, sponsored by Innovation Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 2
- Study locations
NCT03042702 is a Phase 2 study of Ovarian Cancer that has completed, run by Innovation Pharmaceuticals. The registered enrollment target is 2 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03042702, a Phase 2 study of Ovarian Cancer, has completed, sponsored by Innovation Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 2
- Study locations
Study Summary
Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an anti-proliferative p53 activator pharmacological class, for the treatment of cancer. Nonclinical studies have demonstrated that Kevetrin induces apoptosis by activation of wild type p53 and induces apoptosis in mutant p53 cells by degradation of oncogenic mutant p53. In this Phase 2 study, two different short-term treatment regimens of Kevetrin will be evaluated for safety, tolerability, changes in biomarkers/objective tumor response, and to evaluate the pharmacokinetics of Kevetrin when administered to subjects with platinum-resistant/refractory ovarian cancer.
Conditions Studied
Interventions
- DRUG Kevetrin
Study Locations (2)
New Hampshire
- Cancer Research - Lebanon
Texas
- Cancer Research - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2017-11-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03042702
The ClinicalTrials.gov registry entry for NCT03042702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Innovation Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Kevetrin is the first listed.
NCT03042702 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Hampshire, Texas.
Frequently Asked Questions
What is clinical trial NCT03042702 about?
NCT03042702 is a clinical study titled "A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer". Cellceutix has developed Kevetrin (thioureidobutyronitrile), belonging to an anti-proliferative p53 activator pharmacological class, for the treatment of cancer. Nonclinical studies have demonstrated that Kevetrin induces apoptosis by activation of wild type p53 and induces apoptosis in mutant p53 c...
What is the current status of trial NCT03042702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2017-02-09. Estimated completion is 2017-11-10.
What conditions does trial NCT03042702 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03042702?
The interventions under investigation include: Kevetrin (DRUG).
Who is sponsoring clinical trial NCT03042702?
This trial is sponsored by Innovation Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03042702 being conducted?
This trial has 2 study locations across New Hampshire, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.